Buy or sell Mevion Medical Systems stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Mevion Medical Systems Stock

Mevion Medical Systems develops radiation therapies for the treatment of cancer.

About Mevion Medical Systems Stock

Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.

Funding History

October 2007$6.9M
April 2008$10.0M
January 2009$33.0M
March 2011$11.5M
January 2012$45.0M
January 2012$25.0M
June 2013$55.0M
August 2014$200M
August 2015$58.8M
June 2018$150M

Management

Vice President of Regulatory and Quality Assurance

Thomas Faris

Vice President of Engineering

Mark Jones

Vice President Clinical Systems

Stanley Rosenthal

President and Chief Executive Officer

Joseph K. Jachinowski

Chairman

Robert Wilson

Chief Executive Officer

Tina Tianning Yu

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Mevion Medical Systems or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 80K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo